Looking to read the full article? Subscribe to BioWorld.

Aussie stem cell company Regeneus out-licenses Progenza to Kyocera for Japan market

August 12, 2020

PERTH, Australia – Aussie regenerative medicine company Regeneus Ltd. has out-licensed its lead mesenchymal stem cell (MSC) and secretome therapy, Progenza, to Japan’s Kyocera Corp. for osteoarthritis of the knee for the Japan market.

BioWorld Australia Deals and M&A

Already a subscriber? Sign in

Today's news in brief

BioWorld

BioWorld briefs for Sept. 24.

FDA eyes self-administered testing for COVID-19 antigen tests

BioWorld MedTech

The need for self-administered surveillance testing finally has a few candidates, thanks to labs and test developers across the globe, and the U.S. FDA is keen on...

Abbott launches rapid, portable antigen test, increasing COVID-19 testing capacity in France

BioWorld MedTech

PARIS – Abbott Laboratories is launching distribution of its latest Panbio COVID-19 Rapid Test in France.

Today's news in brief

BioWorld MedTech

BioWorld MedTech's briefs for Sept. 24.

New target identified for ZIKV-induced microcephaly

Infection

A study led by Chinese virologists at Southern Medical University (SMU) and Sun Yat-Sen University (SYSU) in Guangzhou has discovered that neural progenitor cell...